Taft Foley III, an 18-year-old high school senior, co-founded Texas Mobile Medical Labs. Photo courtesy of Texas Mobile

An 18-year old high school senior from the Houston area mobilized his medical knowledge as one of the youngest EMTs in Texas and co-founded a mobile lab which can provide COVID-19 results in 15 minutes.

Texas Mobile Medical Labs was created to counteract testing delays that bogged down how quickly patients received results. The mobile lab currently operates in a van and a tent outside a community center in the Post Oak area for patients who prefer to come to them. For those that can't, the mobile lab can travel to any patient or business location for employee testing in the Houston area after they set up an appointment.

"This summer I become an EMT, training at the Texas EMS Academy in Corpus Christi," says Taft Foley III, co-founder of Texas Mobile Medical Labs. "When I got back to Houston I was asked to take a COVID-19 test, but I was met with a line that wrapped around the entire building and took two hours just to get inside."

According to Foley, that spurred him into finding a better way to get results to people quickly.

"I did my research and found a better alternative to increase testing and reduce waiting times," says Taft. "The antigen test works in 15 minutes, which makes them amenable to point-of-care use. That's when I really got the idea of going out to our patients for the test so that they don't have to leave home."

The tests are performed with a nasal swab, which then detects a viral protein in an actively infected person, giving accurate and fast results.

Antigens are molecules capable of stimulating an immune response. The SARS-CoV-2 that causes COVID-19 has several known antigens including its nucleocapsid phosphoprotein and spike glycoprotein, which are the visible protrusions on its surface.

Antigen tests reveal if a person is currently infected with a pathogen such as the SARS-CoV-2 virus. Once the infection is gone, the antigen disappears.

Although antigen tests typically have lower sensitivity than a traditional PCR test, that detects the virus through its genetic material, they provide tests rapidly and are relatively cheaper to produce.

"Getting this test to as many people as possible as fast as possible is essential," says Taft. "People need to know whether or not they need to stay home and if they're at risk of spreading the virus to others."

The results are sent to patients via text message or email, giving individuals peace of mind quickly if they are not infected and allowing those with COVID-19 to quarantine themselves and those they have exposed.

The test cost ranges from $100 to $150 for individuals, according to their website, depending on if testers would like to go to their tent location or take advantage of their mobile lab. While they currently do not accept insurance, most insurance companies will reimburse some or all of the cost of the test.

You can reach the Texas Mobile Medical lab at (936) 333-3333 if you have COVID-19 symptoms and would like to schedule an appointment for testing.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.